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Abstract
The Malaria Policy Advisory Committee to the World Health Organization held its sixth meeting in Geneva,
Switzerland from 10 to 12 September 2014. This article provides a summary of the discussions, conclusions and
recommendations from that meeting.
Meeting sessions covered the following: an update on drug resistance and containment including an assessment
on the feasibility of elimination of Plasmodium falciparum malaria in the Greater Mekong Subregion; guidance on
the control of residual malaria transmission by behaviourally resistant vectors; progress on the implementation of
the Global Plan for Insecticide Resistance Management; updates on the Global Technical Strategy, Global Malaria
Action Plan and the Plasmodium vivax technical brief; gaps in current World Health Organization Global Malaria
Programme guidance for acceleration to elimination; surveillance, monitoring and evaluation; the updated World
Health Organization Guidelines for the Prevention and Treatment of Malaria; Round 5 product testing for rapid
diagnostic tests; and Intermittent Preventive Treatment for infants.
Policy statements, position statements, and guidelines that arise from the Malaria Policy Advisory Committee
meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization
Member States by the World Health Organization Global Malaria Programme.
Keywords: WHO, Malaria, Policy making, Mosquito control, Drug resistance, Surveillance, Elimination, Plasmodium
falciparum, Plasmodium vivax
Background
The Malaria Policy Advisory Committee (MPAC) to the
WHO held its sixth meeting from 10 to 12 September
2014 in Geneva, Switzerland, following its meetings in
February and September 2012, March and September
2013, and March 2014 [1-5]. This article provides a
summary of the discussions, conclusions and recom-
mendations from that meetinga as part of the Malaria
Journal thematic series “WHO global malaria recom-
mendations” [6].
The following sections of this article provide details and
references for the background documents presented at
the open sessions of the committee on: an update on
drug resistance and containment, including an assessment
on the feasibility of Plasmodium falciparum malaria
elimination in the Greater Mekong Subregion; guidance
on the control of residual malaria transmission by mosqui-
toes whose behaviour, such as outside biting, makes them
poorly susceptible to control through Indoor Residual
Spraying (IRS) or long-lasting insecticidal nets (LLINs);
progress on the implementation of the Global Plan for In-
secticide Resistance Management; updates on the Global
Technical Strategy, Global Malaria Action Plan and the
Plasmodium vivax technical brief; gaps in current World
Health Organization Global Malaria Programme guidance
for acceleration to elimination; surveillance, monitoring
and evaluation; the updated World Health Organization
Guidelines for the Prevention and Treatment of Malaria;
Round 5 product testing for rapid diagnostic tests; and
Intermittent Preventive Treatment for infants.
The MPAC discussion and recommendations related
to these topics, which took place partially in closed ses-
sion, are also included. MPAC decisions are reached by
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consensus [7]. The next meeting of the MPAC will be 4
to 6 March 2015 [8].
Report from the WHO global malaria programme
The acting Director of the WHO Global Malaria
Programme (WHO-GMP) provided updates on behalf of
the WHO Americas, African, Eastern Mediterranean,
European, South-East Asian, and Western Pacific Regional
Offices [9]. All regions reported significant progress, but
mentioned important challenges, such as insufficient hu-
man resources which can lead to gaps in technical cap-
acity. This lack of human resource across many technical
areas in malaria programmes is an area of concern to
MPAC members, and has been specifically noted in the
field of entomology and vector control [10].
WHO-GMP also highlighted the key products that
they have released since the last MPAC meeting in
March 2014. These include: the WHO progress report
on the adoption and scaling-up of interventions recom-
mended by WHO in malaria-endemic countries, submit-
ted in response to the UN General Assembly resolution
67/299 on consolidating gains and accelerating efforts to
control and eliminate malaria in developing countries,
particularly in Africa, by 2015 [11]; a report on the plan-
ning meeting for operational research on malaria elimin-
ation [12]; a policy brief on the intensified efforts
required to withdraw oral artemisinin-based monother-
apies from the market, including an overview of WHO’s
recommended regulatory actions and country progress
to date [13]; a manual for elimination scenario planning
which provides a framework to assess scenarios and set
realistic timelines for moving towards elimination based
on programme coverage and funding [14]; and, a report
on the safety and effectiveness of single-dose primaquine
as a P. falciparum gametocytocide [15].
Also mentioned in brief were the results from Round
5 of the WHO product testing of Rapid Diagnostic Tests
(RDTs) [16] and an update on artemisinin resistance
[17] – both of which were also agenda items at the
MPAC meeting and so have separate sections devoted to
them in this meeting report.
In addition, WHO-GMP provided MPAC members
with the results of an online survey to seek feedback on
the MPAC framework, which drew 123 responses from a
variety of stakeholders worldwide [9]. The results indi-
cated some areas for improvement, such as additional
avenues for policy dissemination, but overall appreci-
ation for the strengthened policy making process. MPAC
and WHO-GMP thanked the global malaria community
members who responded to the survey, and also those
who provide regular informal feedback and suggestions
via the WHO-GMP Secretariat. MPAC members thanked
the acting Director, Dr. John Reeder, for his efforts to
assure a harmonious transition and looked forward to
the incoming leadership of Dr. Pedro Alonso, who as-
sumed the post of Director WHO-GMP in mid-October
2014 [18].
Update on drug resistance and containment
The chair of the Drug Resistance and Containment
(DRC) Technical Expert Group (TEG) updated MPAC
on the TEG’s 28-30 April 2014 meeting in Geneva [19].
The information presented included an update on what
was known at the time about Kelch 13 mutation which
has been associated with delayed parasite clearance.
Presence of these mutations is being considered in the
development of new definitions of suspected and con-
firmed artemisinin resistance (see DRC TEG meeting re-
port [20] for more details). The majority of the TEG
update was focused on the feasibility of elimination in
the Greater Mekong Subregion (GMS) as a strategy to
contain multi-drug resistance [21].
The DRC TEG confirmed that P. falciparum resistance
to artemisinin has emerged independently in multiple geo-
graphic areas within the GMS, thus raising concerns about
the effectiveness of a “firewall approach”. At the border
between Cambodia and Thailand, P. falciparum is resist-
ant to almost all available antimalarial drugs. Although
great progress has been achieved recently in reducing the
P. falciparum malaria burden in the GMS through aggres-
sive malaria control measures, this progress is being
threatened by the emergence of multi-drug resistance.
Based on the analysis of the DRC TEG, MPAC recom-
mended to WHO-GMP that it adopt the goal of elimin-
ation of P. falciparum malaria in the GMS by 2030 to
counter the threat of multidrug resistance, including ar-
temisinin resistance, and to prevent its spread. Based on
a feasibility exercise commissioned by WHO-GMP, P.
falciparum elimination in the GMS appears to be tech-
nically and operationally feasible at a reasonable cost,
and is in line with the elimination goals of GMS coun-
tries themselves. It should, therefore, be strongly sup-
ported and pursued urgently while currently available
tools remain effective. MPAC supported the adoption of
this goal by affected countries in the GMS.
MPAC recommended that in order to achieve the goal
of elimination of P. falciparum malaria in the GMS by
2030, an effective joint sub-regional governance structure
that clearly delineates roles and responsibilities of GMS
countries, WHO, and other partners must be established.
An enabling environment must include strong country
leadership, political commitment at all levels, and sustain-
able resource mobilization based on an agreed strategy.
Success will also require enhanced involvement of the pri-
vate sector, and an ongoing coherent research agenda to
inform and enhance elimination efforts. In addition, it will
be necessary to try out and validate novel interventions,
several of which have been identified.
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WHO-GMP will liaise with the WHO South East Asia
and Western Pacific Regional Offices to support the
preparation of an elimination strategy under the coord-
ination of the Emergency Response to Artemisinin Re-
sistance in the GMS (ERAR) hub and the leadership of
the GMS countries and in collaboration with partners.
WHO-GMP will update MPAC on progress made at its
next meeting in March 2015.
Control of residual malaria parasite transmission
The Malaria Vector Control TEG (VC TEG) presented
one of the main outputs from its 24 – 26 February 2014
meeting in Geneva– a review and associated guidance
on the control of residual malaria transmission by mos-
quitoes whose behaviour, such as outside biting, makes
them poorly susceptible to control through core malaria
vector control interventions [22].
The current core malaria vector control interventions
are LLINs [23] and IRS [24], with larval source manage-
ment applicable in certain settings where mosquito
breeding sites are few, fixed and findable [25]. LLINs re-
duce malaria parasite transmission mainly by killing or
blocking mosquitoes that attempt to feed upon humans
under nets. IRS kills mosquitoes and reduces longevity
when they rest on insecticide-sprayed surfaces inside
houses or other structures, usually after feeding on their
occupants. However, the effectiveness of both of these
interventions relies on a number of factors that include
susceptibility of mosquitoes to the insecticides used, ad-
equate coverage rates, quality and timely implementa-
tion, and user acceptance and compliance.
While the factors that can limit the effectiveness of exist-
ing interventions are important and require due attention,
evidence from a variety of settings indicates that residual
malaria parasite transmission occurs even in areas with
good access to and usage of LLINs or well-implemented
IRS [26]. Such transmission is maintained due to a combin-
ation of human and vector behaviours, for example when
human populations reside in or visit forest areas, or are ex-
posed outside houses during mosquito biting times; or
when local mosquito vector species avoid core interven-
tions, for example by resting outdoors away from indoor
treated surfaces. In many malaria-endemic areas, it is likely
that this residual transmission will preclude malaria elimin-
ation in the absence of new vector control interventions.
Technical guidance presented by VC TEG and endorsed
by MPAC was for national malaria control programmes
to prioritize the implementation of current tools whilst
improved or novel vector control interventions are under
development and validation. Potential interventions iden-
tified were those that:
1. Exclude or deter indoor entry using physical
screening barriers or repellents;
2. Following entry, prevent successful indoor feeding
and/or resting using exit or other barriers,
repellents, or insecticides with no deterrent
properties;
3. Prevent successful outdoor feeding by using
insecticide-treated clothing or repellents which
directly protect people;
4. Reduce adult vector densities or transmission
potential by outdoor attractants which lure and
trap/kill mosquitoes, topical or systemic insecticides
for livestock that kill zoophilic mosquitoes during
or after feeding, application of insecticides to
natural sugar sources or by introducing insecticidal
sugar baits.
Robust entomological surveillance-response approaches
are required to characterize the extent and relative contri-
bution of residual transmission to malaria burden across
different settings allowing strategy adjustments that pos-
sibly include the use of vector control tools beyond the
existing core malaria vector control interventions. Once
the supporting evidence base for these novel or improved
interventions is available, policy setting mechanisms within
WHO will make appropriate recommendations for imple-
mentation by national programmes.
Based on MPAC guidance, WHO issued the following
key recommendations to address residual transmission [27]:
1. National malaria control programmes in
collaboration with academic or research institutions
should generate local evidence on the magnitude of
the problem of residual transmission of malaria,
including information on human and vector
behaviour, and intervention effectiveness.
2. Industry and their partners are encouraged to
develop new vector control tools to address residual
transmission. Financial, human and infrastructural
resources are urgently needed to support
development, evaluation and implementation of
such tools.
3. National regulatory authorities should make
renewed efforts to ensure that registration processes
encourage the rapid availability to the local market
of validated new vector control products.
Progress on the implementation of the global plan for
insecticide resistance management in malaria vectors
The Global Plan for Insecticide Resistance Management
in malaria vectors (GPIRM) [28] was launched in May
2012 in response to escalating resistance in Anopheles
mosquitoes. Insecticide resistance has since increased
in frequency, intensity and geographical distribution at
an alarming rate, especially resistance to pyrethroids in
Africa south of the Sahara. At their last meeting in
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March 2014, MPAC requested WHO-GMP to present an
update on the global status of GPIRM implementation.
WHO-GMP reported that some progress has been
made in the global implementation of GPIRM [29], in-
cluding enhanced insecticide resistance monitoring and
the establishment of global and regional insecticide re-
sistance databases. Considerable investments in the de-
velopment of new vector control products have resulted
in new IRS formulations, although there still remain
only four insecticide classes with two modes of action
recommended by WHO for IRS and only one class (py-
rethroids) recommended for use in LLINs.
In general, adoption of GPIRM technical recommenda-
tions to national policy and operational implementation at
the country level has been limited [30]. While some coun-
tries have started to use alternatives to pyrethroids for
IRS, most have yet to establish and implement national in-
secticide resistance monitoring or management plans that
incorporate sound resistance management practices (such
as rotation of insecticides of different modes of action for
IRS). This is due largely to major financial, human and in-
frastructural resource deficiencies and a lack of affordable
alternatives to pyrethroids for IRS and LLINs.
MPAC members expressed deep concern over these
resource deficiencies and at the worsening extent of in-
secticide resistance, which threatens the effectiveness of
malaria vector control. They requested that WHO-GMP
conduct a comprehensive situation analysis and in con-
sultation with malaria endemic countries and their part-
ners prepare a global response plan in order to improve
GPIRM implementation, particularly at country level.
This should include immediate actions to make available
affordable alternatives to pyrethroids for IRS, such as
improved global forecasting, pooled procurements, long-
term contracts and tax incentives.
MPAC members also indicated that malaria endemic
countries need more specific guidance on appropriate
vector control, such as clarification of the potential value
of the addition of IRS to LLIN for either pre-emptive
action against the development of resistance or mitiga-
tion of existing resistance, as well as on the recommen-
dation on frequency of insecticide rotation for IRS. In
the meantime, countries and their implementing part-
ners should continue to develop and implement national
insecticide resistance monitoring and management plans
that include alternatives to pyrethroids for IRS. These
activities should be incorporated into national malaria
control strategies.
Updates on the global technical strategy for malaria
(2016 - 2030), global malaria action plan 2, and the
Plasmodium vivax technical brief
Following support from WHO Member States at the
2013 World Health Assembly to develop a global malaria
strategy for the post-2015 period, and a detailed discussion
on an early draft at the March 2014 MPAC meeting, seven
regional consultations were held between March and June
2014. The regional consultations gathered input on the
initial draft from more than 400 experts representing
national malaria programmes, ministries of health, re-
search organizations, and implementing partners. Follow-
ing the regional consultations, a revised draft was prepared
for a web consultation of WHO Member States, consult-
ation participants, and malaria stakeholders that took place
in July and August 2014. The process, outlined in the ses-
sion presentation [31], was led by WHO-GMP and sup-
ported by both MPAC and a dedicated Steering Committee
of leading malaria experts, scientists, and representatives
from malaria-endemic countries.
The result of these many activities is a near-final draft
Global Technical Strategy for Malaria 2016-2030 that
provides a framework to develop tailored programmes
to accelerate progress towards malaria elimination for
whole countries and sub-national areas. It defines a clear
and ambitious path for endemic countries and global
malaria partners, and milestones for the next 15 years
up to 2030. It emphasizes the need to achieve universal
coverage of the core package of malaria interventions for
all populations at risk and highlights the importance of
using real-time data for decision-making to drive re-
sponses consistent with national or sub-national goals.
The draft strategy identifies where innovative solutions
will be essential to fully achieve the strategy’s goals, and
describes the financial implications of strategy imple-
mentation. Importantly, the document also references
key WHO-recommended guidance documents and will
be updated regularly to incorporate significant innova-
tions in tools and approaches.
MPAC members, having reviewed the near-final WHO
technical strategy as part of the background documents
for the meeting, expressed appreciation of the inclusive
country-driven consultation process that had taken place,
and approved the way in which the draft WHO technical
strategy is now framed. Further inputs from WHO Re-
gional Offices and the Regional Committee meetings were
incorporated before it was submitted for discussion at the
136th meeting of the Executive Board to the World Health
Assembly in January 2015. It is expected that the draft
WHO technical strategy will be submitted to the World
Health Assembly in March 2015, for review as an agenda
item at their meeting in May 2015.
Concurrent with the development of the Global Tech-
nical Strategy, the Roll Back Malaria (RBM) Partnership
has been coordinating the development of the Global
Malaria Action Plan 2 (GMAP2) [32]. This action plan,
whose draft structure and content were outlined by the
co-chair of the GMAP2 Task Force [33], will support the
implementation of the draft WHO technical strategy
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through global advocacy, resource mobilization, partner
harmonization, and the engagement of non-health sectors.
Both documents are being developed in a collaborative
process, involving an overlap in steering committees, and
will be jointly launched in 2015 to provide a strengthened
platform for continuing malaria investments in the
broader post-2015 development agenda. Because GMAP2
is a RBM Partnership document, it will be approved by
the RBM Board rather than adopted by the World Health
Assembly and its timeframe allows it to complement the
final version of the draft WHO technical strategy. A dedi-
cated website for GMAP2 is already collecting ideas [32];
and an on-line general public consultation on the docu-
ment is expected to begin in early 2015.
WHO-GMP also provided MPAC with an update on
the development of the technical brief on Plasmodium
vivax malaria, which will consolidate all P. vivax-specific
guidance into one document for the first time [34]. After
some discussion on the format and release options for
this technical brief, MPAC concluded that the technical
brief was a suitable support document for the draft
WHO technical strategy, although renaming might be
needed to ensure it is not confused as a separate strat-
egy. MPAC members favoured a 2015 release date, in-
cluding a closely timed publication of a policy-oriented
executive summary and research-oriented journal sup-
plement, before the formal launch of the WHO Global
Technical Strategy and GMAP2 later in 2015.
MPAC commended the GTS Steering Committee, the
GMAP2 Task Force, and WHO-GMP on progress to date
with all three documents, and the leadership of WHO-
GMP and RBM on the close alignment of the processes
for the draft WHO technical strategy and GMAP2. MPAC
members expressed sincere thanks to those observers
attending the meeting and to malaria stakeholders every-
where for their support of and participation in the consult-
ation process.
Gaps in current WHO-GMP guidance on malaria elimination
WHO-GMP sought the advice of MPAC on how to ad-
dress gaps in its guidance to countries on achieving mal-
aria elimination [35]. The current WHO field manual on
malaria elimination for low and moderately endemic
countries [36] was produced in 2007 and has not been
updated since then; it will shortly be reviewed. The pur-
pose of the field manual is to inform national govern-
ments from endemic countries, partner and donor
agencies and field managers about the issues related to
malaria elimination, and to serve as a tool in the imple-
mentation, monitoring and evaluation of malaria elimin-
ation programmes.
Malaria elimination aims for the sustainable interrup-
tion of local malaria transmission despite a continued
presence of malaria vector mosquitoes and potential
importation of parasites through international travel and
migration. In areas with intense transmission and ex-
treme poverty, where overall health and development
are still weak, the priority is good malaria control using
proven tools, such as appropriate case management
using accurate diagnostics and effective drugs with
artemisinin-based combination therapy, and vector con-
trol with indoor residual spraying and insecticide-treated
mosquito nets.
Programme reorientation towards elimination may be
considered in areas where essential clinical services are
available, the basic needs of the population are covered,
malaria transmission has been reduced to a level where
less than 5% of all febrile patients suspected of having
malaria carry malaria parasites, and case-loads are be-
coming manageable. WHO-GMP explained that the aim
in the pre-elimination phase is to set up the quality-
controlled systems required for the elimination phase,
which should then be fully implemented when malaria
incidence has been reduced to less than 1 infection per
1000 people at risk per year.
At present, WHO-GMP grants certification of malaria
elimination to countries that have interrupted local
transmission for a period of three or more years and
have high-quality surveillance systems that provide cred-
ible evidence supporting the absence of ongoing local
transmission. However, WHO-GMP asked MPAC and
those observers present at the MPAC meeting if the
scope of the field manual should be expanded by omit-
ting the specification “for low and moderate endemic
countries”.
MPAC members suggested that WHO-GMP should
conduct a stakeholder survey similar to that which sup-
ported the new edition of the WHO Guidelines for the
Prevention and Treatment of Malaria (MTGs). The sub-
sequent changes required to the field manual, if any, will
determine the need to convene an Evidence Review
Group (ERG) to expand the field manual’s scope.
WHO-GMP also proposed an ERG on Mass Drug
Administration (MDA- all the people in a broad geo-
graphic area are given malaria drugs without any screen-
ing), Mass Screening and Treatment (MSAT – all the
people in a broad geographic area are screened, regard-
less of whether they have symptoms of malaria), and Fo-
cused Screening and Treatment (FSAT –screening all
the people in a defined geographical area and providing
treatment for those who test positive) [37,38]. MDA
has received renewed interest over the last decade in
the context of malaria elimination initiatives and as
part of artemisinin resistance containment efforts. In
2010, WHO held a consultation which reviewed some
of the past experience with MDA and screening pro-
grammes, their potential advantages and disadvantages,
and highlighted the need for more research to define
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better their potential role in malaria control, in particular
in elimination programmes.
Now that new research has accrued, MPAC approved
the establishment of an ERG on the role of MDA,
MSAT and FSAT for malaria transmission reduction and
elimination to:
a) review all available published and unpublished
reports on the impact of MDA, MSAT and FSAT on
malaria transmission, building on a recent Cochrane
Review and an additional review from Global Health
Group;
b) review results of experiences/unpublished studies of
large-scale implementation of MDA in Comoros, at
the Thai-Myanmar border, and Zanzibar; and of
MSAT in Zambia and other locations;
c) evaluate the additional role of concomitant
administration of low-dose primaquine (0.25 mg
base/kg) as a gametocytocide for P. falciparum
together with the artemisinin-based combination
therapy (ACT) when deployed for MDA;
d) define the specific conditions under which MDA,
MSAT and FSAT should be deployed to reduce
malaria transmission in terms of endemicity, drugs
and dosages, diagnostics, timing and number of
MDA rounds, concomitant implementation of
vector control measures and best strategies to
ensure community uptake and pharmacovigilance;
e) identify research gaps and provide recommendations
on data requirements, study methods and ethical
considerations for research groups and policy
makers interested in further evaluating the role of
MDA, MSAT and FSAT in reducing malaria
transmission.
Originally, WHO-GMP had proposed that the ERG be
convened in December 2014, but noted that additional
study data would be available by mid-2015. MPAC agreed
that the ERG should wait to include the additional data in
the evidence review. The ERG will present its findings to
MPAC either in March or September 2015, depending on
when the evidence review can take place.
Surveillance, monitoring and evaluation
The Chair of the Surveillance, Monitoring and Evaluation
(SME) TEG updated MPAC on its first two meetings
(14-16 May and 26-27 August 2014), both of which had
taken place since the last MPAC meeting in March 2014.
Much of the SME TEG’s activities so far have involved
reviewing the estimation of global malaria indicators, the
draft technical strategy for 2016-2030 in which surveil-
lance plays a major role, and indicators for the Sustain-
able Development Goals [39]. At the country level, the
SME TEG has advised WHO-GMP on chemoprevention
indicators, and manuals on programme monitoring, health
facility surveys, and Malaria Programme Reviews.
In terms of future work, the SME TEG’s immediate
priority is to construct and to develop a framework for
malaria SME to enable a baseline to be established for
monitoring progress against the goals of the draft WHO
technical strategy. The TEG also plans to help WHO-
GMP create guidance for countries on improving data
quality, data capture in the private sector, and capacity
building in surveillance and monitoring and evaluation.
The TEG’s plans and priorities for its future meetings
were strongly welcomed and encouraged by MPAC, as
was the opportunity to work closely with RBM’s Moni-
toring and Evaluation Reference Group (MERG) and
others, to avoid conflicting messages to countries and to
donors such as the Global Fund. MPAC also encouraged
the SME TEG not to focus too heavily on modelling, but
to assist countries to improve the quality of their data so
that modelling would not be as necessary.
The SME TEG plans to meet twice a year, and will up-
date MPAC on its outputs and outcomes accordingly.
WHO guidelines for the prevention and treatment of malaria
The Co-chair of the Chemotherapy TEG updated MPAC
on progress with developing the third edition of the WHO
Guidelines for the Prevention and Treatment of Malaria
(MTGs) [40,41]. The MTGs provides comprehensive, glo-
bal and evidence-based guidelines for the formulation of
policies and national guidelines for the treatment of mal-
aria. The Guidelines were first published in 2006 and the
second edition was published in 2010 [42]. The MTGs
have been produced under the guidance of the TEG on
Malaria Chemotherapy.
A draft plan for revision and update of the second edi-
tion was presented and endorsed at the meeting of the
MPAC in September 2012; updates of the review process
had been presented to the MPAC at the March 2013
and March 2014 meetings [2,3,5].
The third edition of the MTGs, as in previous editions,
provide guidelines on malaria treatment, including a new
section on intermittent preventive treatment, the latest
scientific evidence of in vitro anti-malarial susceptibility,
safety, and the pharmacokinetic and pharmaco-dynamic
properties of the different anti-malarial medicines. The
guidelines take into account varying levels of malaria drug
resistance and background immunity between areas, as
well as the operational and feasibility aspects of malaria
chemotherapy in severely resource-constrained settings.
Based on the results of a recent online survey, during
which respondents expressed satisfaction regarding the
format of the MTGs, the overall format of the new MTGs
has been retained.
The recommendations of the updated MTGs (third
edition) were finalized at the last malaria Chemotherapy
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TEG in June 2014 and were presented to MPAC for rati-
fication. MPAC members approved the recommenda-
tions which included prompt diagnosis and effective
treatment, intermittent preventive treatment, and modi-
fications to the dosage of anti-malarials for small chil-
dren. The MPAC expressed concern over the sometimes
confusing categories of evidence strength that accom-
pany the MTG recommendations. However, they con-
cluded that changing an internationally recognized, and
now WHO-adopted, method of evidence review (The
Grading of Recommendations Assessment, Development
and Evaluation, otherwise known as GRADE) was be-
yond their remit. They urged WHO-GMP to make the
GRADE categories/nomenclature explicit to countries
when disseminating the MTGs, to avoid any confusion
about the strength of the MTG recommendations and
the evidence base for them.
It is expected that the MTGs will undergo final clearance
by the WHO Guidelines Review Committee and other
WHO in-house processes by the end of 2014. The third
edition of the MTGs is expected to launch in early 2015.
Round 5 product testing for rapid diagnostic tests
WHO-GMP provided MPAC members with a background
and overview of the product testing process, new results
from the latest round of testing, and the WHO procure-
ment criteria for rapid diagnostic tests, and an insight on
the market trends and impact of repeated rounds of prod-
uct testing on manufacturers [43].
The results of the latest round of product testing were
well received. MPAC members and procurers (namely the
Global Fund and US Presidents Malaria Initiative who
were present at the MPAC meeting) acknowledged that
while product testing remains a voluntary process, with
submission of products at the discretion of the manufac-
turer, there is continued value in the testing programme
due to the positive influence it exerts on market quality.
A full copy of the Round 5 Product Testing Report, in-
cluding an executive summary, is available on the WHO-
GMP website [16,44].
Intermittent preventive treatment and mortality
Intermittent Preventive Treatment in infancy (IPTi) is a
malaria control intervention based on the administration
of a full therapeutic course of an anti-malarial to all infants
at risk of malaria delivered at the time of administration of
routine Expanded Programme on Immunization (EPI)
vaccines – usually at 10 weeks, 14 weeks, and about
9 months of age. IPTi with sulphadoxine-pyrimethamine
(SP) was recommended by WHO in 2010 for areas with
moderate-to-high malaria transmission, where resistance
to SP is not high [45].
Concern about the absence of an overall effect of IPTi
on mortality was raised in 2012 [46]. Noting that a study
at Navrongo, Ghana, had found a (statistically non-
significant) clustering of deaths in young infants aged
12-14 weeks, who had received SP within the previous
month [47], MPAC subsequently recommended that
WHO-GMP support a study to analyze mortality data in
eight trials which had evaluated the efficacy of IPTi. The
findings from this review were reviewed by MPAC. It
was noted that the trials that had been conducted did
not have the power to detect a small reduction in mor-
tality and members of the committee were reassured
that no increase in mortality or clustering in young in-
fants within 30 days after SP administration had been
observed in trials other than the one conducted at Nav-
rongo [Aponte et al., personal communication].
MPAC concluded that considering the marked, statisti-
cally significant protective efficacy of IPTi against all-
cause hospital admissions, it is likely that it also decreases
mortality, but it is recognized that such an effect has not
been documented directly. IPTi with SP can be a cost-
effective strategy for reducing malaria morbidity in infants
and MPAC urged those countries where IPTI would po-
tentially be beneficial to consider its implementation.
Discussion
The wording for recommendations were finalized by
MPAC during their closed session following the two days
of open sessions; conclusions have been included in the
summaries of the meeting sessions above, and links to the
full set of meeting documents are provided as references.
Position statements and policy recommendations made
by the MPAC have been issued formally and disseminated
to WHO Member States by WHO-GMP and the WHO
Regional Offices. Conclusions and recommendations from
MPAC meetings are published in the Malaria Journal as
part of this series.
Feedback from the MPAC meeting will also be given to
and received from the global malaria community at the
RBM Board meeting in December 2014, through the pub-
lication of this article, and subsequent correspondence.
On-going engagement with and attendance by inter-
ested stakeholders at MPAC meetings continues to be en-
couraged. In addition to open registration for MPAC
meetings, which will continue (via the WHO-GMP web-
site starting in January 2015) and attendance by four
standing observers (RBM, the Global Fund, UNICEF, Of-
fice of the UN Special Envoy for Financing the Health Mil-
lennium Development Goals and for Malaria), the active
participation of seven rotating National Malaria Control
Programme representatives and all six WHO Regional
Malaria Advisors adds to the value of these consultations.
Conclusion
The meeting feedback received from MPAC members,
participants and observers [48] was generally positive.
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Having met six times to date, the format of MPAC meet-
ings and its feedback loops with other advisory bodies and
stakeholders is fairly settled. As noted by the MPAC stake-
holder survey [9] and as with any policy-setting process,
there are some areas where there is room for improve-
ment; these suggestions will be taken into consideration
for future meetings and policy dissemination. WHO-GMP
and the MPAC continue to welcome feedback, support,
and suggestions for improvement of MPAC meetings from
the global malaria community. The next meeting of the
MPAC will take place from 4 to 6 March 2015 in Geneva,
Switzerland. Further information including the agenda and
registration details will be made available in January 2015
on the MPAC page of the WHO-GMP website, although
questions are welcome at any time [8].
Endnote
aThe complete set of all MPAC September 2014 meeting-
related documents including background papers, presenta-
tions, and member declarations of interest can be found
online at http://www.who.int/malaria/mpac/sep2014/en/.
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